Adrian Sacher, M.D.

Lung oncologist, tumor immunology & KRAS researcher, advocate for lung cancer patients and learners @pmcancercentre, @uoftmedicine, @UofT. He/Him/Il. 🏳️‍🌈

[Adrian Sacher, M.D. @DocSacher]

Setting the bar higher for KRAS inhibitors - pleased to share our study of divarasib in KRAS G12C lung/colon/solid tumors in @NEJM. Impressive response rate, durability and tolerability. Thanks to pts and co-investigators. @KRASKickers #lcsm

[NEJM @NEJM]

Among patients with cancers bearing the KRAS G12C mutation who received divarasib at a 400-mg dose, 56% with lung cancer, 36% with colorectal cancer, and 36% with other tumor types had a confirmed response.

🔗 Read the full study results: https://t.co/qhLT0MvQx8

#oncology

[International Lung Cancer Summit @LungSummit]

🚨 Check our Top 10 #LungCancer abstracts for ELCC 2026!
We've hand-picked the must-see sessions with times & presenters.
🗓️ Stay on track in Copenhagen and simply import these directly to your calendar by clicking this link:
https://t.co/ewiGwzCVah

Which lung abstracts are your favorites at ELCC26 #LCSM @IASLC @myESMO

[ESMO - Eur. Oncology @myESMO]

📣 Updated ESMO #ClinicalPracticeGuideline on early & locally advanced #NSCLC: new systemic treatments, innovative strategies & advanced therapeutic options to personalise #PatientCare & improve outcomes.

🔗 https://t.co/BPNEfzhl5e

#LungCancer #SystemicTherapy #Oncology #CancerTreatment

[Lung Cancer Canada @LungCancer_Can]

����️ New #LungCancerVoices Podcast episode! @pwheatleyprice & @DocSacher talk about all there is to know about #KRAS lung cancer. What is KRAS, how it's tested, what it means in terms of treatment options for those who have this subtype.

▶️ Listen now at https://t.co/D2ce0QvtKF

[The Oncologist @OncJournal]

Early phase trials: the perils of nonpublication
@DocSacher @susanebates
https://t.co/IIhAxRpeD2

[Natalie Vokes @NIVokes]

It was a pleasure to spend the day @ASCO planning the metastatic NSCLC program with this amazing group (missing Toby Campbell). Looking forward to an exciting #ASCO25 !

[Annals of Oncology @Annals_Oncology]

@HPrenen #ESMO24 concomitant paper: @DocSacher presents the First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor at today's Presidential Symposium @HPrenen

[OncLive.com @OncLive]

AMG 193 Shows Preliminary Clinical Activity in MTAP-Deleted Solid Tumors @DocSacher @pmcancercentre @uoftmedicine @UofT #ESMO24 #ESMO2024 #MedTwitter https://t.co/AQQSWFPaTZ

[Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD]

Excellent summary of #KRASG12C trials in the metastatic NSCLC space by @DocSacher @ASCO #ASCO24
✨ 2L tx TKI v. Docetaxel
✨ combination TKI + IO
✨ combination with chemo
✨ combination with EGFR
Lot if interest in this space and congrats to all the authors @OncoAlert

[Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD]

Excited for #ASCO24! While disease specific content is best found in oral session dedicated to a disease group, explore thematic Clinical Science Symposia that are a highlight - such as the special session on #KRAS In #NSCLC
📍Hall B1, Sat, Jun 1 @TonyMok9 @DocSacher @KCArbourMD

[Patrick Forde @FordePatrick]

Not one, not 2, but 3 lung cancer plenaries at #ASCO24 ! Early telemed pall care, the LAURA trial of consolidation osimertinib after CRT for stage 3 EGFR non small cell lung cancer & the ADRIATIC trial of consolidation immunotherapy after CRT for small cell lung cancer! #lcsm

[Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD]

Next up #TTLC24 Targeted Therapies: KRAS, BRAF, SHP2, SOS1 kicks off w/ @FSkoulidis @Dobeze_ @DrMarkAwad @AlexSpiraMDPhD @SukiPadda @kamarroneMD @NaglaAKarimMD @DocSacher @NIVokes!

[Brad Wouters 🇨🇦 @bradwouters]

Pleased to participate in #Coalition4CdnResearch press conference with all Canadian advocacy groups coming together to call on the federal government to invest in research. @cafreeland @KirstyDuncanMP @JustinTrudeau

[Brad Wouters 🇨🇦 @bradwouters]

Exciting new clinical findings from @DocSacher @pmcancercentre @UHN_Research demonstrating potential of targeting KRAS

[Lung Cancer Foundation of America @lcfamerica]

🌟 Dr. @DocSacher's research uncovers potential treatments for lung cancer patients facing drug resistance. With LCFA backing, he takes crucial steps towards a brighter future for those battling lung cancer. #Livingwithlungcancer #WLCD23 #lungcancer https://t.co/ijheV30KSJ

[Lung Cancer Foundation of America @lcfamerica]

🔬 Dr. @DocSacher's mission is to comprehend the body's immune response to cancer cells. With LCFA's support, he explores novel therapies that may transform treatment approaches. 🌱 #Livingwithlungcancer #LCFAmerica #LCFAResearch #WLCD23 #lungcancer https://t.co/ijheV30KSJ

[Adrian Sacher, M.D. @DocSacher]

The support of @lcfamerica and patients & their families has been essential to our ongoing work to end lung cancer. Thank you so much - great things to come!

[Lung Cancer Foundation of America @lcfamerica]

🎓 As a Clinical Investigator and Assistant Professor, Dr. @DocSacher's impact on lung cancer research is undeniable. His dedication to immunotherapy brings hope to patients worldwide. 🏆 #Livingwithlungcancer #LCFAResearch #WLCD23 #lungcancer https://t.co/ijheV30KSJ

[CrozrX @CrozrX]

Canadian Consensus Recommendations on the Management of KRASm G12C #NSCLC #KRAS 🫁
🔻
https://t.co/ZzZYl85C0e

[Susan Bates @susanebates]

Upfront Atezolizumab Poses Lower Risk of Hyperprogression in NSCLC https://t.co/tgyLdGM94A

[Adrian Sacher, M.D. @DocSacher]

Really amazing data on GDC-6036 plus cetuximab in KRAS G12C metastatic colon cancer - ORR 62% !!! More potent KRAS G12C inhibitors make for more effective combos & better options for patients. #AACR23 @KRASKickers